Recent developments, challenges and future prospects in advanced drug delivery systems in the management of tuberculosis

Tuberculosis (TB) is reported as one of the most prevailing life-threatening health problems, affecting almost one third of the population globally. It is one of a major reason of death with an imposing amplified socio-economic impact. Tuberculosis patients have infrequent endocrine and metabolic derangements, but they are important when they occur. Multiple drug regimen, poor patient compliance, and stiff administration schedule are factors that are answerable for the development of and extensive drug resistance (XDR) and multi drug resistance (MDR) instances in TB along with poor drug targeting effects. The emerging resistance strains and high transmittance rate of the disease have prompted the need for studies in advanced drug delivery, particularly nanotechnology for the management of TB. Nanocarriers offer unique physicochemical properties that provide beneficial outcomes such as targeted effects and better patient compliance as drug delivery, thereby presenting as a promising solution to the constraints linked with conventional treatment strategy for TB. Both in vitro and in vivo studies have been reported to access release behavior of antitubercular agents with a view to being interpreted in clinical practice in the future. The present review highlights contemporary trends and advancements in drug delivery systems employed for the effective management of TB. This communication will be useful to the researchers working in the field of drug delivery systems for effective management of TB.